Improvement of antioxidant status in women conventionally treated for breast cancer after 12 months of a cow milk whey-based supplementation. A preliminary study
Cancer chemo- and radiotherapy are constantly associated with unwanted side effects at least partially ascribable to oxidative stress, an imbalance between pro-oxidant and antioxidant factors. However, the possible indication and efficacy of antioxidant supplementations — including glutathione-based formulas — aimed to restore the oxidative balance should be, respectively, evaluated and monitored carefully with reliable analytical tools.
Because previous studies on cystic fibrosis and athletes showed that high-cysteine-content, whey-based formulas were able to improve glutathione levels in cystic fibrosis and in healthy exercising people, the aim of this preliminary study was to evaluate the impact on oxidative balance of a new antioxidant supplementation, based on a high-cysteine formula containing a protein mimicking breast milk, on women conventionally treated for breast cancer.
Subjects and methods
Twenty women suffering from breast cancer under ambulatory conventional antineo-plastic treatment were supplemented for 12 consecutive months with 10 g u.i.d. of an oral nutraceutical lipid- and lactose-free formula containing a mix of peptides from cow’s milk whey having a high content of cysteine and glutamic acid as the main biochemical precursor of glutathione (Prother®, DMF Limbiate, MI, Italy). During the study period the recruited subjects underwent a periodical (bimonthly) clinical visit, during which they were tested for oxidative balance (BAP test and d-ROMs). Before and at the end of the study the women were invited to complete the Spitzer Questionnaire.
Plasma antioxidant capacity, as detected by the BAP test, showed a marked early trend towards a progressive increase, reaching statistical significance at the end of the treatment (2319.5 ± 288.7 vs. 1894.5 ± 362.5 μmol/l reduced iron, respectively; p = 0.007). Plasma oxidant status, as measured by means of the d-ROMs test, after an irregular time-course, increased significantly at the 12th month, compared to the baseline value (350.29 ± 39.29 vs. 407.00 ± 58.54 CARR U, respectively; p = 0.0017). The treatment was well tolerated.
The breast milk-mimicking protein formula intake was associated with a restoration of biological antioxidant potential, maybe by increasing the bioavailability of antioxidant components, and reduced glutathione, with no apparent interference with the intrinsic pharmacological/chemical mechanism (oxidant species generation) of the current treatment (chemo/radiotherapy).
This preliminary study indicates that 12 months of regular oral intake of a high-content cysteine nutraceutic formula is associated with increased plasma antioxidant capacity in women conventionally treated for breast cancer. Moreover, the data from oxidative status assessment suggest that the above supplement did not interfere with oxidant production, the increase of which is related to the cancer and antineoplastic treatment itself. Finally, the d-ROMs and BAP tests were shown to be very reliable tools to monitor ambulatory oxidative balance in this kind of patient.
KeywordsOxidative stress Antioxidants d-ROMs test BAP test Whey proteins
Unable to display preview. Download preview PDF.
- 2.Halliwell B, Gutteridge JMC (1999) Free radicals in biology and medicine, 3rd Edn. Clarendon Press, OxfordGoogle Scholar
- 3.Juránek I, Bezek S (2005) Controversy of free radical hypothesis: reactive oxygen species — cause or consequence of tissue injury? Gen Physiol Biophys 24:263–278Google Scholar
- 4.Beinert T, Binder D, Stuschke M et al (1999) Oxidant-induced lung injury in anticancer therapy. Eur J Med Res 4:43–53Google Scholar
- 6.Simone CB 2nd, Simone NL, Simone V, Simone CB (2007) Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, part 1. Altern Ther Health Med 13:22–28Google Scholar
- 8.Dohi K, Satoh K, Ohtaki H et al (2005) Elevated plasma levels of bilirubin in patients with neurotrauma reflect its pathophysiological role in free radical scavenging. In Vivo 19:855–860Google Scholar
- 11.Mantovani G, Maccio A, Madeddu C et al (2003) The impact of different antioxidant agents alone or in combination on reactive oxygen species, antioxidant enzymes and cytokines in a series of advanced cancer patients at different sites: correlation with disease progression. Free Radic Res 37:213–223CrossRefGoogle Scholar
- 14.Ivkovic S, Zabcic D (2002) The effect of tribomechanically activated zeolite (TMAZ) on total antioxidant status of healthy individuals and patients with malignant disease. Free Radic Biol Med 33[Suppl 1]Google Scholar
- 15.Martarelli D, Pompei P (2009) Oxidative stress and antioxidant changes during a 24-hours mountain bike endurance exercise in master athletes. J Sports Med Phys Fitness 49:122–127Google Scholar
- 17.Stringer AM, Gibson RJ, Bowen JM et al (2007) Chemotherapy-induced mucositis: the role of gastrointestinal microflora and mucins in the luminal environment. J Support Oncol 5:259–267Google Scholar
- 20.Trotti R, Carratelli M, Barbieri M (2002) Performance and clinical application of a new, fast method for the detection of hydro-peroxides in serum. Panminerva Med 44:37–40Google Scholar
- 22.Cornelli U, Terranova R, Luca S et al (2001) Bioavailability of some food supplementations in men and women using the d-ROMs test as a marker of oxidative stress. J Nutr 131:3208–3211Google Scholar
- 23.Fracchiolla NS, Guggiari E, Maissonneuve P et al (2001) Oxidative stress in myelodysplastic syndromes: increased levels of reactive oxygen metabolites and homocysteine. Blood 98:271bGoogle Scholar
- 31.La Torre F, Orlando A, Silipigni A et al (1996) Increase of oxygen free radicals and their derivatives in chemo- and radiation treated neoplastic patients. Minerva Med 86:1–4Google Scholar
- 33.Lands LC, Grey VL, Smountas AA (1999) Effect of supplementation with a cysteine donor on muscular performance. J Appl Physiol 87:1381–1385Google Scholar
- 34.Li Y, Schellhorn HE (2007) New developments and novel therapeutic perspectives for vitamin C. J Nutr 137:2171–2184Google Scholar